R-CHOP±依鲁替尼III期试验中DLBCL免疫组化与基因表达分型的比较
基于PHOENIX III期试验,评估免疫组化(IHC)与基因表达谱(GEP)在判定弥漫大B细胞淋巴瘤(DLBCL)细胞起源(COO)上的一致性。总体生存结局按COO或治疗分组相似,但<60岁ABC型DLBCL患者中依鲁替尼联合R-CHOP较安慰剂联合R-CHOP显著改善总生存和无事件生存。
要点
- <60岁ABC型DLBCL患者中,依鲁替尼+R-CHOP较安慰剂+R-CHOP显著改善OS和EFS。
- 总体人群生存结局按COO或治疗分组未见显著差异。
核心结论
- IHC与GEP在判定DLBCL细胞起源上高度一致,且测试患者中生存结局一致,提示集中IHC可用于富集对依鲁替尼联合R-CHOP应答的人群。
研究设计与样本
- 基于PHOENIX III期临床试验,比较IHC与GEP判定DLBCL细胞起源的一致性。
- 筛查1114例患者中910例IHC判定为non-GCB;入组837例中746例IHC确认为non-GCB。
主要发现
- 总体生存结局按COO或治疗分组相似。
临床怎么用
- 集中IHC可用于筛选non-GCB DLBCL患者,以富集可能从依鲁替尼联合R-CHOP获益的人群。
- 对<60岁ABC型DLBCL患者,可考虑依鲁替尼联合R-CHOP治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without ibrutinib. Among 910 of 1114 screened patients with non-germinal centre B cell-like (non-GCB) DLBCL by IHC, the concordance with GEP for non-GCB calls was 82·7%, with 691 (75·9%) identified as activated B cell-like (ABC), and 62 (6·8%) as unclassified. Among 746 of 837 enrolled patients with verified non-GCB DLBCL by IHC, the concordance with GEP was 82·8%, with 567 (76·0%) identified as ABC and 51 (6·8%) unclassified; survival outcomes were similar regardless of COO or treatment, whereas among patients with ABC DLBCL aged <60 years, the overall and event-free survival were substantially better with ibrutinib versus placebo plus R-CHOP [hazard ratio (HR) 0·365, 95% confidence interval (CI) 0·147-0·909, P = 0·0305; HR 0·561, 95% CI 0·326-0·967, P = 0·0348, respectively]. IHC and GEP showed high concordance and consistent survival outcomes among tested patients, indicating centralised IHC may be used to enrich populations for response to ibrutinib plus R-CHOP.
引用
- Balasubramanian S, Wang S, Major C, et al. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. Br J Haematol. 2021. PMID: 33942292. doi:10.1111/bjh.17450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。